# Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

> **NCT04566328** · PHASE3 · RECRUITING · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 1450 (estimated)

## Conditions studied

- Plasma Cell Myeloma
- RISS Stage I Plasma Cell Myeloma
- RISS Stage II Plasma Cell Myeloma

## Interventions

- **DRUG:** Bortezomib
- **BIOLOGICAL:** Daratumumab and Hyaluronidase-fihj
- **DRUG:** Dexamethasone
- **DRUG:** Lenalidomide
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT04566328
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-24
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 1450 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- National Cancer Institute (NCI)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04566328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04566328, "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04566328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*